Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 4:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 3,922 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Tract Infections (RTI) Clear all
Completed Phase 2 Interventional Results available

H1N1 Vaccine at Two Dose Levels in HIV Positive Adults

NCT00992433
View directory record Official record
Conditions
Influenza
Interventions
Inactivated Influenza H1N1 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Oct 11, 2026, 4:43 PM EDT
Completed Not applicable Interventional

A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients

NCT00000947
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
19
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 11, 2026, 4:43 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults

NCT05975840
View directory record Official record
Conditions
Influenza, Human
Interventions
FLU Q-PAN H5N8 375_B, FLU Q-PAN H5N8 375_A, FLU Q-PAN H5N8 750_B, FLU Q-PAN H5N8 750_A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
20
States / cities
Anniston, Alabama • Mobile, Alabama • Tempe, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 11, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults

NCT02233816
View directory record Official record
Conditions
Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions
Low dose of quadrivalent VLP vaccine, Medium dose of quadrivalent VLP vaccine, High dose of quadrivalent VLP vaccine, Placebo
Biological
Lead sponsor
Medicago
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Hollywood, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 11, 2026, 4:43 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Influenza A 2009 H1N1 Challenge Study in Healthy Adults

NCT01646138
View directory record Official record
Conditions
Influenza
Interventions
Ca/04/2009/H1N1 Vero Grown Challenge Virus
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 11, 2026, 4:43 PM EDT
Active, not recruiting Not applicable Interventional

Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses

NCT05864118
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Respiratory pathogen panel PCR test, COVID-19 antibody test
Diagnostic Test
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 11, 2026, 4:43 PM EDT
Completed Not applicable Interventional

Clinical Evaluation of Safety and Efficacy for the NEUROMARK System in Subjects With Chronic Rhinitis (PARAGON)

NCT05591989
View directory record Official record
Conditions
Chronic Rhinitis
Interventions
NEUROMARK System
Device
Lead sponsor
Neurent Medical
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Birmingham, Alabama • California City, California • Temecula, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 11, 2026, 4:43 PM EDT
Completed No phase listed Observational

Optimizing Clinical Use of Polymyxin B

NCT02682355
View directory record Official record
Conditions
Pneumonia, Blood Stream Infection, Urinary Tract Infections, Respiratory Tract Infection (Including Tracheobronchitis), Sepsis
Interventions
Not listed
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 11, 2026, 4:43 PM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone)

NCT05736874
View directory record Official record
Conditions
Covid19
Interventions
Fluticasone, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
87
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 11, 2026, 4:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Echinacea, Propolis and Vitamin C for URI Prevention in Preschoolers

NCT00231218
View directory record Official record
Conditions
Common Cold, Gastroenteritis
Interventions
dietary supplement--echinacea, propolis, and vitamin c
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
3 Years to 6 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 14, 2006 · Synced Oct 11, 2026, 4:43 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)

NCT04575597
View directory record Official record
Conditions
Coronavirus Disease (COVID-19)
Interventions
Molnupiravir, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
32
States / cities
Peoria, Arizona • Los Angeles, California • North Hollywood, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 11, 2026, 4:43 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness

NCT04610047
View directory record Official record
Conditions
Influenza, Influenza -Like Illness
Interventions
Norketotifen, Placebo
Drug
Lead sponsor
Emergo Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • DeBary, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 11, 2026, 4:43 PM EDT
Withdrawn Phase 1 Interventional

Sirolimus in COVID-19 Phase 1

NCT04371640
View directory record Official record
Conditions
SARS-CoV-2, Covid-19
Interventions
Sirolimus 1 MG/ML, Placebo
Drug
Lead sponsor
Walter K. Kraft
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 11, 2026, 4:43 PM EDT
Withdrawn Phase 1 Interventional

Validation of Aspiration Markers in Intubated Patients

NCT02598713
View directory record Official record
Conditions
Pneumonia, Aspiration
Interventions
Aspiration Marker
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 11, 2026, 4:43 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID

NCT06597396
View directory record Official record
Conditions
Post-COVID Condition, Fatigue Symptom
Interventions
Abrocitinib, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 11, 2026, 4:43 PM EDT
Completed Not applicable Interventional

A Multifaceted Intervention to Improve Prescribing for Acute Respiratory Infection for Adults and Children in Emergency Department and Urgent Care Settings

NCT03022929
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Enhanced Antimicrobial Stewardship Commitment and Feedback
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Sacramento, California • Torrance, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 11, 2026, 4:43 PM EDT
Completed No phase listed Observational

CZI Rare As One: Co-designing an App and Wearable Based Compass for Rare Diseases

NCT06907953
View directory record Official record
Conditions
Pancreatitis, Chronic, Sarcoidosis, VCP Disease, Long COVID, PCD, Symptoms and Signs, Wearables
Interventions
Observational - no intervention
Other
Lead sponsor
4YouandMe
Other
Eligibility
14 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 11, 2026, 4:43 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD)

NCT01048879
View directory record Official record
Conditions
Critically Ill Renal Failure Requiring CVVHD and Oseltamivir, Critically Ill Requiring ECMO and Oseltamivir
Interventions
pharmacokinetic blood sampling, pharmacokinetic blood and dialysate sampling
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 21, 2012 · Synced Oct 11, 2026, 4:43 PM EDT
Not listed No phase listed Observational

Genetic Mechanisms Underlying SARS-CoV-2 Infection and the Impact of COVID-19 on Cognitive Function

NCT04506229
View directory record Official record
Conditions
Covid19
Interventions
Whole exome sequencing
Genetic
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Oct 11, 2026, 4:43 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

NCT03959488
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
MEDI8897, Palivizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
0 Years to 1 Year
Enrollment
925 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
30
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 11, 2026, 4:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of Oral Rinses for Inactivation of COVID-19 (MOR2)

NCT05178173
View directory record Official record
Conditions
COVID-19, Coronavirus Infection, SARS CoV 2 Infection
Interventions
Placebo Comparator: Sterile Water, 27% Ethanol plus essential oils, 0.075% Cetylpyridinium Chloride
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 11, 2026, 4:43 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19

NCT04828161
View directory record Official record
Conditions
COVID-19
Interventions
ensovibep, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
27
States / cities
Jasper, Alabama • Colton, California • Fullerton, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 11, 2026, 4:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Galactooligosaccharide, Immune Strength, and Digestive Health in Older Adults Over Cold and Flu Season

NCT01302561
View directory record Official record
Conditions
Healthy
Interventions
Sucrose, Galactooligosaccharide
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
60 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 11, 2026, 4:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pilot Study of Genotypic Analysis

NCT00421837
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
50 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 16, 2013 · Synced Oct 11, 2026, 4:43 PM EDT